Qlife Holding AB

Equities

QLIFE

SE0013486552

Medical Equipment, Supplies & Distribution

Delayed Nasdaq Stockholm Other stock markets 06:59:47 2024-04-30 am EDT			5-day change	1st Jan Change
0.0028 ^SEK	-6.67%		-15.15%	-85.93%

Apr. 05	Qlife Places Danish Operational Company in Reconstruction Mode	MT
Mar. 25	Sweden's Qlife to Launch Biomarker Testing Platform in South Korea Via Potential Partnership	MT

Qlife informs that it has put its Danish operational company into reconstruction mode as a temporary measure

April 04, 2024 at 10:15 am EDT

Under Danish law the company can during a reconstrution phase resolve on creditor issues and access certain loans.

"Qlife is following our operational plans, but since we have a called for an extraordinary general meeting later this month to resolve on the company's balance sheet, we have chosen at the same time to use this measure under Danish law to resolve some creditors issues. We consider this step as an additional option to secure the liquidity balance in the short term.", says Thomas Warthoe CEO of Qlife.

This disclosure contains information that Qlife Holding AB is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 04-04-2024 16:14 CET

For more information please contact:

Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34

https://news.cision.com/qlife-holding-ab/r/qlife-informs-that-it-has-put-its-danish-operational-company-into-reconstruction-mode-as-a-temporary,c3956679

Latest news about Qlife Holding AB

Qlife Places Danish Operational Company in Reconstruction Mode	Apr. 05	MT
Sweden's Qlife to Launch Biomarker Testing Platform in South Korea Via Potential Partnership	Mar. 25	MT
Qlife Signs Letter of Intent with Precision Biosensor	Mar. 25	CI
Qlife Secures Core Patent for Egoo System in EU, UK Markets	Feb. 23	MT
Qlife Announces its Core Patent for Egoo System Grants in EU and Other Countries in European Market, as Well as in United Kingdom	Feb. 23	CI
Qlife Holding AB Announces Update on Collaboration with Hipro Biotechnology	Feb. 16	CI
Qlife Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 09	CI
Qlife Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 09	CI
Qlife Holding AB Postpones the Publication of the Year-End Report for the Financial Year 2023 Until 8 February 2024	Feb. 04	CI
Qlife Enters Collaboration Agreement with Hipro Biotechnology	Dec. 07	CI
Qlife, Hipro Biotechnology Ink Collaboration Deal for Egoo Health; Shares Soar	Dec. 04	MT
Qlife Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Qlife Secures Chinese Partner for Egoo Health; Stock Surges 44%	23-09-14	MT
Qlife Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-17	CI
Qlife Holding AB announced that it has received SEK 4.647035 million in funding from Pensys Ab, Jinderman & Partners AB	23-08-02	CI
Qlife Holding AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-16	CI
Qlife Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-16	CI
Qlife Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-25	CI
Qlife Plans Layoffs, Cost Reductions; Shares Down 11%	22-09-30	MT
Qlife Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-24	CI
Qlife Plunges 18% as It Seeks Up to $17 Million from Rights Issue	22-08-24	MT
Scanfil Signs Deal To Take Over Medical Device Manufacturing For Qlife	22-08-15	MT
Qlife Signs Outsourcing Agreement with Scanfil to Take over the Continued Production of the Egoo Device	22-08-15	CI
Qlife Receives Milestone Payment of USD 1.23 million from FIND	22-06-27	CI
Qlife Jan Gorm Lisby First to Join Scientific Advisory Board	22-06-20	CI

Chart Qlife Holding AB

Duration

Period

More charts

Company Profile

Qlife Holding AB is a Sweden-based medical technology Company that manufactures the hardware and software platform Egoo.health (Egoo) with which patients can carry out various types of biomarker tests based on a small amount of blood. Egoo performs analyzes that correlate to over 99 percent with high-performance laboratory instruments. The Egoo instrument measures biomarkers for the chronic diseases Phenylketonuria (PKU), rheumatoid arthritis (RA) and cancer. Qlife Holding is the parent company of the wholly owned Danish medical technology subsidiary Qlife ApS. Qlife ApS develops a medical technology product with the long-term goal of giving people access to safe and valid biomarker data at home.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-06 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
QLIFE HOLDING AB	-85.93%	177K
ABBOTT LABORATORIES	-3.29%	186B
MEDTRONIC PLC	-2.56%	107B
BECTON, DICKINSON AND COMPANY	-4.44%	67.44B
DEXCOM, INC.	+2.59%	50.03B
CENCORA, INC.	+16.55%	47.81B
HOYA CORPORATION	+4.79%	41.03B
METTLER-TOLEDO INTERNATIONAL, INC.	+2.69%	26.85B
WEST PHARMACEUTICAL SERVICES, INC.	+3.76%	25.82B
ZIMMER BIOMET HOLDINGS, INC.	-0.81%	25.01B

Other Medical Equipment, Supplies & Distribution